Baxter (NYSE:BAX) said today that it closed its $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz. According to the deal, Baxter gains Claris’ portfolio of injectable generics and three manufacturing plants. The Deerfield, Ill.-based company said it plans to add new aseptic manufacturing and lyophilization capabilities, as well as invest in new technology platforms, […]
Pharmaceuticals
Amgen shares fall after Q2 earnings reveal ‘bare’ pipeline
Shares in Amgen (NSDQ:AMGN) fell today even though the biotech topped expectations on Wall Street with its second quarter results. The Thousand Oaks, Calif.-based company posted profits of $2.2 million, or $2.91 per share, on sales of $5.8 billion for the 3 months ended June 30, for bottom-line growth of 15% on sales growth of […]
New GSK chief taps WalMart exec, refocuses R&D efforts
GlaxoSmithKline‘s (NYSE:GSK) has reportedly named former WalMart executive Karenann Terrell as chief digital and technology officer, in a move to integrate digital technology across its pharmaceutical business. This is among the many choices made by newly appointed chief executive Emma Walmsley to boost GSK’s ability to compete with rival pharma companies. GSK also recently nabbed […]
Roche taps Accenture’s analytics tech for digital diabetes management
Accenture (NYSE:ACN) said today that it inked a five-year deal with Roche (OTC:RHHBY) to incorporate its analytics platform into Roche’s digital diabetes management system. According to the deal, Roche’s new digital “diabetes ecosystem” will be built on the Accenture Intelligent Patient Platform. The system reportedly allows Roche to collect and analyze data from diabetes patients in […]
Kala nabs $104m in IPO
Kala Pharmaceuticals (NSDQ:KALA) said today that it closed its initial public offering of 6.9 million shares of common stock. The Waltham, Mass.-based company priced its public offering at $15.00 per share, granting underwriters an option to buy up to 900,000 additional shares. The exercise of this option brought the proceeds of its IPO up from $90 […]
Surmodics to launch pivotal trial for drug-coated balloon
Surmodics (NSDQ:SRDX) said today that it won investigational device exemption from the FDA to launch a pivotal trial of its SurVeil drug-coated balloon. The trial is slated to compare the Eden Prairie, Minn.-based company’s device with Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon for patients with peripheral artery disease in the upper leg. “By providing a head-to-head comparison […]
Biogen lifts outlook after strong Q2
Shares in Biogen (NSDQ:BIIB) rose today after the biopharmaceutical company met expectations on Wall Street with its second quarter results. The Cambridge, Mass.-based company posted profits of $863 million, or $4.07 per share, on sales of $3.1 billion for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 6% compared […]
Lilly tops Q2 earnings, revenue estimates
Shares in Eli Lilly (NYSE:LLY) fell today even though the drugmaker beat expectations on Wall Street with its second quarter results. The Indianapolis-based company posted profits of $1.01 billion, or 95¢ per share, on sales of $5.82 billion for the 3 months ended June 30, for bottom-line growth of 35% on sales growth of 8% compared […]
India approves Anika’s Monovisc osteoarthritis treatment
Anika Therapeutics (NSDQ:ANIK) said today that regulatory authorities in India approved its single injection viscosupplement, Monovisc, as a therapy for pain associated with osteoarthritis in synovial joints. The Bedford, Mass.-based company’s product is already available in the U.S. Canada and Europe. Anika said it hopes to expand into Australia, New Zealand and other international markets in the […]
AntriaBio launches trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that the first patient was dosed in a Phase I first-in-human trial of its once-weekly basal insulin. The single ascending dose study is designed to test the safety, pharmacokinetics and dynamics of AB101 in patients with Type I diabetes. The second part of the study is slated to compare AB101 to Sanofi‘s […]